Ibrain(OA期刊)(国际刊号)

Ibrain(OA期刊)(国际刊号) 知网目次

基本信息
  • 主管单位:

  • 主办单位:

    遵义医科大学附属医院

  • 国际刊号:

    2313-1934;EISSN 2769-2795

  • 国内刊号:

  • 学科分类:

    神经|精神病学

  • 字数:

    -

  • 有无基金:

     

  • 周期:

    国际号刊-季刊

  • 特殊属性:

    外文期刊

联系信息
  • 电话:

    0851-28608507(官网电话)

  • 邮箱:

    Ibrain@idragon.org.cn(202401期)

  • 复合因子:

    0

  • 综合因子:

    0

  • 收录:

    知网目次

  • 级别:

期刊简介

《Ibrain(OA期刊)(国际刊号)》期刊已被查看:

更新频次

单位占比

一作占比

投稿指南

1、该刊只有国际刊号。

2、投稿方式:在线投稿。

3、刊内网址:(202401期)

https://onlinelibrary.wiley.com/journal/27692795

4、投稿系统:https://mc.manuscriptcentral.com/ibra

5、主办单位网址:

http://www.zmuhospital.com/Article/Class-334.html

(遵义医科大学附属医院)

6、刊内邮箱:Ibrain@idragon.org.cn

7、官网电话:0851-28608507

8、期刊刊期:季刊,逢季末月出版。

9、微信公众号:遵义医科大学附属医院(ZYykdxffyy)

2024年5月15日星期三

《Ibrain》投稿指南

【官网信息】

Ibrain

Author Guidelines

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/ibra.

Click here for more details on how to use ScholarOne.

Data protection:

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

Preprint policy:

Please find the Wiley preprint policy here.

Ibrain will consider articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.

For help with submissions, please contact: Ibrain@idragon.org.cn

2. AIMS AND SCOPE

Ibrain is an international and open access journal in the field of neuroscience. The journal publishes the advanced research about brain function, brain network, brain structure and brain imaging, and provides a communication platform about basic & translational science and clinical practice for neuroscientists. Ibrain welcomes submissions all over the world that will benefit the development of neuroscience.

Ibrain is interested in the topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology or artificial intelligence. The journal is focused on clinical and experimental advances that provide the disease characteristics, pathogenic mechanism or medical techniques.

Topics of interest include, but are not limited to:

Cellular and molecular neuroscience

Regeneration and plasticity

Development and stem cells

Cognition and psychiatric disorders

Neurodegeneration and repair

Neurodegenerative diseases

Stroke

Brain injury

Spinal cord injury

Cerebral ischemia

Brain tumor

Nerve injury

Head injury

Neural circuit

Neural technology

Neuropathy

Cerebral ischemia and hypoxia

Head and face disease

Neuralgia

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Original article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make significant contribution to the scientific knowledge in neuroscience areas. Typically, the research will provide insight into an as yet unknown mechanism or poorly understood process, constitute a highly significant contribution to our understanding of neuroscience, and be of general interest to the neuroscience community. Research articles are typically 6000 words in length, with up to 12 figures and tables in total, and no limitation on the number of references.

Reviews, including systematic reviews and meta-analyses, are typically written by leading experts in the filed within the journal’s scope. Reviews papers help specialists to keep up with the current state of knowledge in a specific research area and provide informative message for non-specialists. Reviews aim to be a critical and concise overview of the most recent advances in a specific research field. Reviews will typically be no limitation on words in length, with up to 8 figures and tables in total, and no limitation on the number of references.

Comments discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Comments can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance. Comments are typically 3000 words in length, with up to 4 figures and tables in total and no more than 70 references.

Case reports emphasize all aspects of clinical neuroscience. They should describe: (a) unique cases that may represent a previously undescribed condition; (b) unexpected association of two or more diseases; (c) adverse or unexpected treatment response; (d) any other clinical observation based upon well-documented cases that provides important new information; or (e) a new or revised clinical technique or procedure.

Letter provides the rapid and concise report of a novel discovery that is brief in nature and should be of general interest to the field of neuroscience. Letters are typically 1200 words in length excluding, references, figures and tables, with up to 1 figures and tables in total, and no more than 10 references.

Methods are news-style reports, and are published a few times a year to review techniques and technologies in fast-moving fields of research. For further information, contact  Ibrain@idragon.org.cn.

4. PREPARING THE SUBMISSION

Cover Letters

Authors may include recommended or non-recommended reviewers in the cover letter. Cover letters are not mandatory; however, they may be supplied at the author’s discretion.

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);

A short running title of less than 40 characters;

The full names of the authors;

The author's institutional affiliations where the work was conducted, with  a footnote for the author’s present address if different from where the work was conducted;

Abstract and keywords;

Main text;

Ethical statement

Acknowledgments;

Conflict of interest

Funding

Transparency statement

Authors' contribution

References;

Tables (each table complete with title and footnotes);

Figure legends;

Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

For the benefit of the reviewers and editors, please include line numbers in your main text files.

Abstract

Please provide an abstract of 250 words containing the major keywords summarizing the article.

Keywords

Please provide three to six keywords.

Main Text

The journal uses British/US spelling; however, authors may submit using either option, as spelling of accepted papers is converted during the production process.

Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter

……

更多详情:

https://onlinelibrary.wiley.com/page/journal/27692795/homepage/author-guidelines

中国全科医学发文选摘

  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

常见问题

  • 哪些期刊可以用来评职称?

    1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。

  • 你们的服务可以保证文章被发表吗?

    期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。

  • 请问发表一篇期刊的费用是多少?

    期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。

  • 如果发表不成功可以退款吗?

    如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。

  • 请问文章发表需要多长时间?

    不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。

  • 期刊发表能加急见刊吗?

    为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。